(a) Objectives 1. To assess the full lung function, exercise capacity, quality of life in patients with COVID-19 over 2 years. 2. To assess the longevity of the serology response to SARS-CoV2. 3. To investigate the association of the neutralization titer in plasma from different vaccinated cohorts to its protection of infection using in vivo model 4. To investigate the SARS-CoV-2 specific cellular and humoral immunities as well as their determinant factors from community subjects who have received different types of COVID-19 vaccines. 5. To assess the third booster dose for subjects who have poor antibody response despite having received two doses of CoronaVac (Sinovac)
The health conditions of adults (N=300) who recovered from varying severity of COVID-19 will
be assessed and their blood are collected at 6, 12, 24 and 36 months after discharge. The
assessment package includes: lung function tests, 6-min walk distance, chest radiographs/CT,
and SF36 General Health questionnaire. Blood samples from community cohorts will be collected
from before and up to 36 months after receiving one of the three COVID-19 vaccines (N=200 per
vaccine type). The kinetics of SARS-CoV-2 specific humoral and cellular immunities from both
convalescent and vaccinated cohorts are determined by neutralization assay and by measuring
specific T cell responses upon stimulation of SARS-CoV-2 specific peptide library
respectively. The antiviral level of the human plasma with various neutralization titer
collected from different vaccinated cohorts will be tested in mouse model and ADCC assay.
Biological: third dose vaccination with CoronaVac vaccine
Healthy individuals with low antibody levels after 2 doses of CoronaVac vaccine to receive one additional dose of CoronaVac vaccine
Biological: third dose vaccination with BionTech vaccine
Healthy individuals with low antibody levels after 2 doses of CoronaVac vaccine to receive one additional dose of BionTech vaccine
Biological: Vaccination with Coronavac vaccine
Healthy individuals to receive Coronavac vaccine 2 doses, 21 days apart
Biological: Vaccination with BionTech Vaccine
Healthy individuals to receive BionTech vaccine 2 doses, 21 days apart
Inclusion Criteria: Patients who have been discharged from hospital following treatment for
COVID-19 -
Exclusion Criteria: Unwilling to be follow up
-
Prince of Wales Hospital
Hong Kong, Hong Kong
Investigator: Susanna So-Shan Ng
Contact: 3505 2785
drsssng123@yahoo.com.hk
Susanna Ng, MBChB
85235053128
drsssng@gmail.com
Karen Yiu, BSc
85235053532
ysyiu@cuhk.edu.hk
David S Hui, MD, Principal Investigator
Chinese University of Hong Kong